Hepatocellular Carcinoma (HCC) Market Research Report-Size, Share, Growth, and Trend Analysis | Forecast (2022 - 2032)
The Hepatocellular Carcinoma (HCC) Market represents a highly specialized segment within the oncology landscape, focusing on the treatment and management of liver cancer, primarily HCC, which accounts for approximately 90% of all primary liver cancer cases. This market encompasses a wide array of innovative therapies, ranging from targeted agents to immunotherapy, aimed at addressing unmet clinical needs. As the incidence of liver cancer rises globally due to factors like hepatitis infections and non-alcoholic fatty liver disease, the market is poised for substantial growth driven by novel advancements in therapeutics.
Disruptive Impact and Opportunities:
HCC treatment is undergoing transformative changes, presenting immense opportunities for stakeholders. Emerging therapies are introducing groundbreaking mechanisms of action, promising enhanced efficacy and improved patient outcomes. Additionally, the integration of immunotherapy with targeted therapies has paved the way for synergistic combination treatments, revolutionizing the standard of care. These advancements offer streamlined administration protocols and safer therapeutic options while catering to a vast patient population.
Emerging Drugs:
- H3B-6527
- GNS561
- SAR445256
- Cabozantinib
Marketed Drugs:
- CYRAMZA (ramucirumab)
- KEYTRUDA (pembrolizumab)
- TECENTRIQ (atezolizumab)
- JEMPERLI (dostarlimab)
- OPDIVO (nivolumab)
- YERVOY (ipilimumab)
Key Companies:
- Can-Fite BioPharma
- Sinocelltech
- AVEO Oncology
- Oxford BioTherapeutics
- Beijing SyngenTech
- Surface Oncology
- Novartis Oncology
- Array BioPharma
- Taizhou Hanzhong Pharmaceuticals
- Akeso Biopharma
Market Segmentation:
By Type
· Targeted Therapy
- Tyrosine Kinase Inhibitors (TKIs)
- Monoclonal Antibodies
· Immunotherapy
- Immune Checkpoint Inhibitors
- Other Immunomodulators
· Chemotherapy
- Cytotoxic Drugs
· Radiotherapy
- External Beam Radiation Therapy (EBRT)
- Internal Radiation Therapy (Selective Internal Radiation Therapy - SIRT)
· Surgical Intervention
- Liver Resection
- Liver Transplantation
· Ablation Therapy
- Radiofrequency Ablation (RFA)
- Microwave Ablation (MWA)
· Other Treatments
- Combination Therapies
- Emerging Therapies
By Administration Type
· Oral Administration
· Injectable Administration
- Intravenous (IV)
- Subcutaneous (SC)
- Intramuscular (IM)
· Localized Administration
- Transarterial Chemoembolization (TACE)
- Transarterial Radioembolization (TARE)
What’s in It for You?
- Gain insights into cutting-edge drug development and competitive landscapes.
- Identify lucrative opportunities in emerging drug classes and combination therapies.
- Understand evolving market dynamics for strategic investment decisions.
- Leverage detailed analysis to strengthen market positioning and gain a competitive edge.
Hepatocellular Carcinoma (HCC) Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)
1. Hepatocellular Carcinoma (HCC) Market - Executive Summary
1.1. Introduction
1.2. Objectives
1.3. Key Findings
1.3.1. Market Size 2025 & 2030: By Key Country (10MM)
1.3.2. Global Market Size 2025 & 2030: By Key Segment
1.3.3. Key Investments & Startup Analysis
1.4. Research Methodology
2. Understanding the Disease
2.1. Disease Overview
2.2. Classification
2.3. Signs and Symptoms
2.4. Risk Factors
2.5. Causes
2.6. Disease Biology & Digital Innovations
2.7. Stages & Staging System
2.8. Diagnostic Algorithm
2.9. Current Treatment Practices & Algorithm
2.10. Current Standard of Care and Treatment Gaps
2.11. Patient Demographics and Treatment Pathways
3. Guidelines
4. Unmet Needs
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 10MM
5.3. Epidemiology Scenario: 10MM
5.4. U.S. Epidemiology Scenario
5.5. EU-5 Epidemiology
5.5.1. U.K. Epidemiology Scenario
5.5.2. Germany Epidemiology Scenario
5.5.3. France Epidemiology Scenario
5.5.4. Italy Epidemiology Scenario
5.5.5. Spain Epidemiology Scenario
5.6. Japan Epidemiology Scenario
5.7. China Epidemiology Scenario
5.8. Australia Epidemiology Scenario
5.9. India Epidemiology Scenario
6. Real-world Data & Real-world Evidence
7. Drug Development Landscape
7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies
7.1.1. KEYTRUDA (pembrolizumab)
7.1.1.1. Product Description
7.1.1.2. Regulatory Milestones
7.1.1.3. Other Developmental Activities
7.1.1.4. Pivotal Clinical Trials
7.1.1.5. Ongoing Current Pipeline Activity
7.1.2. CYRAMZA (ramucirumabis)
7.1.2.1. Product Description
7.1.2.2. Regulatory Milestones
7.1.2.3. Other Developmental Activities
7.1.2.4. Pivotal Clinical Trials
7.1.2.5. Ongoing Current Pipeline Activity
7.1.3. TECENTRIQ (atezolizumab)
7.1.3.1. Product Description
7.1.3.2. Regulatory Milestones
7.1.3.3. Other Developmental Activities
7.1.3.4. Pivotal Clinical Trials
7.1.3.5. Ongoing Current Pipeline Activity
7.1.4. JEMPERLI (dostarlimab)
7.1.4.1. Product Description
7.1.4.2. Regulatory Milestones
7.1.4.3. Other Developmental Activities
7.1.4.4. Pivotal Clinical Trials
7.1.4.5. Ongoing Current Pipeline Activity
7.1.5. OPDIVO (nivolumab)
7.1.5.1. Product Description
7.1.5.2. Regulatory Milestones
7.1.5.3. Other Developmental Activities
7.1.5.4. Pivotal Clinical Trials
7.1.5.5. Ongoing Current Pipeline Activity
7.2. Competitive Analysis and Differentiation
7.3. Overview of Similar/Competing Drugs in Clinical Trials
7.4. Future Trends and Emerging Drugs
7.4.1. H3B-6527
7.4.1.1. Product Description
7.4.1.2. Clinical Development
7.4.1.3. Safety and Efficacy
7.4.2. GNS561
7.4.2.1. Product Description
7.4.2.2. Clinical Development
7.4.2.3. Safety and Efficacy
7.4.3. SAR445256
7.4.3.1. Product Description
7.4.3.2. Clinical Development
7.4.3.3. Safety and Efficacy
7.4.4. Cabozantinib
7.4.4.1. Product Description
7.4.4.2. Clinical Development
7.4.4.3. Safety and Efficacy
8. Regulatory Strategy and Potential Challenges
8.1. Regulatory Pathways in Key Markets
8.2. Anticipated Regulatory Hurdles and Mitigation Strategies
8.3. Case Studies in Oncology Drug Regulation
8.4. Impact of Potential Changes to Regulatory Framework
9. Commercial Landscape
9.1. Market Size & Growth Rates
9.2. Key Approvals & Anticipated Loss of Exclusivity
9.3. PESTLE & Porter’s Five Forces Analysis
9.4. Market Shares, Positioning/Ranking
9.5. Market Drivers
9.6. Identification of Threats
9.7. Digital Evolution in Commercialization
10. Market Segmentation
10.1. Market by Therapy Type
10.1.1. Chemotherapy
10.1.2. Radiation Therapy
10.1.3. Surgery
10.1.4. Targeted Therapy
10.1.5. Immunotherapy
10.1.6. Others
11. Pricing, Reimbursement, and Access
11.1. Competitive Pricing Analysis
11.2. Reimbursement Landscape and Challenges
11.3. Strategies for Market Access and Equity
11.4. Patient Spending/Expenditure Analysis
12. Future Trends, Disruptions, and Opportunities
12.1. Analysis of Emerging Trends
12.2. Technological Impact
12.3. Impact of Potential Market Disruptors
12.4. Opportunities for Future Development and Expansion
12.5. Considerations for Investment Opportunities
13. Global Market Dynamics
13.1. Regional Regulatory Disparities
13.2. Cross-Border Partnership Strategies
13.3. Global Supply Chain Dynamics
13.4. Case Studies: Success and Failure in Global Markets
13.5. Strategies for Global Expansion and Localization
14. Company Profiles
14.1. Can-Fite BioPharma
14.2. Sinocelltech
14.3. AVEO Oncology
14.4. Novartis Oncology
14.5. Shanghai Henlius Biotech
14.6. Chugai Pharmaceutical
14.7. CStone Pharmaceuticals
14.8. Shenogen Pharma
14.9. GlaxoSmithKline Oxford BioTherapeutics
Download Sample
Choose License Type
2500
4250
5250
6900
